A5054345142- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Economic and Financial Impacts of Cancer
- Adipokines, Inflammation, and Metabolic Diseases
- Colorectal and Anal Carcinomas
- Pancreatic and Hepatic Oncology Research
Tampere University
2019-2025
Tampere University Hospital
2019-2025
BackgroundAnti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection limited. We hypothesised that markers systemic inflammation would predict adverse outcomes multiple treated with anti-PD-(L)1 agents.Material and methodsDiscovery cohort consisted patients who were anti-programmed cell death protein-1 (PD-1) advanced melanoma (MEL), non-small lung cancer (NSCLC) or renal bladder (GU) at Oulu University Hospital had pretreatment C...
8011 Background: Durvalumab consolidation after chemoradiotherapy (CRT) has improved clinical outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC). Despite durvalumab treatment, a substantial proportion of relapse, while up to 20% achieve long-term survival without durvalumab. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection shown promise as tool for risk-adaptive and personalized treatment strategies resectable NSCLC but is still...
Anti-PD-(L)1 agents have revolutionized the treatment paradigms of non-small cell lung cancer (NSCLC), while predictive biomarkers are limited. It has been previously shown that systemic inflammation, indicated by elevated C-reactive protein (CRP) level, is associated with a poor prognosis in anti-PD-(L)1 treated. The aim study was to analyze prognostic and value CRP addition traditional markers tumor PD-L1 score. We identified all NSCLC patients (n = 329) who had undergone proportion score...
Non-small cell lung cancer (NSCLC) is a leading cause of mortality in the Western world. However, emerging treatment options and more patients directed to active treatments might improve outcomes. Here, we retrospectively studied patient characteristics practices for NSCLC Finland 2014-2019 with special focus on changes trends over time.The cohort consisted diagnosed 2014-2018. Cancer were followed until end 2019. The data, both structured unstructured, collected from electronic medical...
The aim of this descriptive study is to analyze the cost for treatment NSCLC and SCLC patients (2014-2019) in Finland. primary objective understand recent developments.The retrospective based on hospital register data. population consists diagnosed four out five Finnish university hospitals. final sample included 4047 766 patients.Cost lung cancer increasing. Both average first 12 months as well 24 after diagnosis increases over time. For 2014, was 19,000 €and those 2015 22,000 €. annual...
According to the CONCORD-3 study, 5-year survival rate of lung cancer patients in Finland has not improved during twenty-first century. In present we evaluated trends diagnosed and treated one five university hospitals determine possible explanatory factors behind lack survival.This retrospective population-based study included all Tampere University Hospital 2007-2019 (N = 3041). The population was divided into two subcohorts: 2007-2012 those 2013-2019. subcohorts were then compared analyze...